TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025.
The fireside chat is scheduled for Tuesday, December 2, 2025 at 12:30 PM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events.
Positive
- None.
Negative
- None.
Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ET
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025. The fireside chat is scheduled to take place on Tuesday, December 2, 2025, at 12:30 PM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When will TG Therapeutics (TGTX) present at the Evercore Healthcare Conference in 2025?
Who will represent TG Therapeutics (TGTX) at the December 2025 Evercore Healthcare Conference?
How can investors watch the TG Therapeutics (TGTX) fireside chat on December 2, 2025?
What are the dates of the 8th Annual Evercore Healthcare Conference where TGTX will appear?
Will the TG Therapeutics (TGTX) fireside chat at Evercore be available after the live event?
Where is the TG Therapeutics (TGTX) Evercore presentation listed for investor access?
